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Spatial concordance of DNA methylation classification
in diffuse glioma
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Abstract
Background. Intratumoral heterogeneity is a hallmark of diffuse gliomas. DNA methylation profiling is an
emerging approach in the clinical classification of brain tumors. The goal of this study is to investigate the effects
of intratumoral heterogeneity on classification confidence.
Methods. We used neuronavigation to acquire 133 image-guided and spatially separated stereotactic biopsy
samples from 16 adult patients with a diffuse glioma (7 IDH-wildtype and 2 IDH-mutant glioblastoma, 6 diffuse
astrocytoma, IDH-mutant and 1 oligodendroglioma, IDH-mutant and 1p19q codeleted), which we characterized
using DNA methylation arrays. Samples were obtained from regions with and without abnormalities on contrastenhanced T1-weighted and fluid-attenuated inversion recovery MRI. Methylation profiles were analyzed to devise
a 3-dimensional reconstruction of (epi)genetic heterogeneity. Tumor purity was assessed from clonal methylation
sites.
Results. Molecular aberrations indicated that tumor was found outside imaging abnormalities, underlining the
infiltrative nature of this tumor and the limitations of current routine imaging modalities. We demonstrate that
tumor purity is highly variable between samples and explains a substantial part of apparent epigenetic spatial
heterogeneity. We observed that DNA methylation subtypes are often, but not always, conserved in space taking
tumor purity and prediction accuracy into account.

© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
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Conclusion. Our results underscore the infiltrative nature of diffuse gliomas and suggest that DNA methylation subtypes are relatively concordant in this tumor type, although some heterogeneity exists.
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Key Points
• Tumor purity is an important consideration for DNA methylation-based glioma
classification.

Importance of the Study
Genetic and transcriptional intratumoral heterogeneity
is a key feature of diffuse gliomas and thought to drive
treatment failure. Epigenetic profiling is an emerging
approach used for clinical classification of brain tumors that results in improved alignment of patients and
treatments. However, how epigenetic intratumoral heterogeneity may impact the robustness of classification
remains unclear. Through DNA methylation profiling of
multiple spatially mapped biopsies from diffuse gliomas
in 16 adult patients and 11 patients in a validation cohort,
our study shows that epigenetic spatial heterogeneity

Diffuse gliomas are the most common malignant brain tumors in adults.1 Patients with a diffuse glioma have a poor
prognosis and eventually succumb to treatment failure.2
The diagnosis, treatment, and follow-up of diffuse gliomas
rely heavily on imaging,2 with magnetic resonance imaging
(MRI) as the current standard. Using contrast-enhanced
T1-weighted (T1c) MRI, diffuse gliomas can be divided
into enhancing tumors, predominantly glioblastoma, or
non-enhancing tumors, predominantly low-grade gliomas
(LGG).T1c MRI is used for enhancing andT2/fluid-attenuated
inversion recovery (FLAIR) MRI for non-enhancing gliomas.3
However, diffuse glioma infiltration extends beyond the abnormalities detected on standard MRI.4,5 Also, the majority
of diffuse gliomas recur directly adjacent to the standard
MRI-guided surgical cavity.6 Heterogeneity of tumor cells
is a salient feature of diffuse gliomas and thought to be a
driver of treatment failure. Treatment exposure may drive
the clonal evolution of heterogeneous tumor cell populations, leading to the selection and survival of resistant
subpopulations in some gliomas, whereas refractory disease in others may be driven by other factors.7
Numerous studies have looked at genetic and
transcriptomic heterogeneity in diffuse glioma. Recent
single-cell transcriptome studies have elucidated transcriptional heterogeneity in regulatory programs that converge on the cell cycle or distinct cellular states8,9 while
bulk tissue analysis has demonstrated extensive heterogeneity in somatic drivers such as EGFR and PDGFRA10,11 as
well as in general somatic alteration burden.12–14
DNA methylation is an epigenetic modification where
a methyl group is added to cytosine, most commonly

is confounded by the presence of non-tumor cells and
the prediction accuracy of the classifier. Taking these
confounders into account, DNA methylation-based
classification is conserved in space in most patients,
including tumor presence outside standard imaging abnormalities. These findings emphasize the importance
of tumor purity assessment in DNA methylation studies.
The uniformity of DNA methylation-based classification within tumors demonstrates the robustness of this
method for classification, corroborating its value for
clinical studies and practice.

measured in the CpG dinucleotide context. These modifications are of interest to the neuro-oncology field as genomewide patterns in DNA methylation profiles provide a robust
method for disease classification and a viable supplement
to traditional histopathology.15,16 Nevertheless, the extent
of intratumoral heterogeneity in DNA methylation remains
unclear.
To improve our understanding of the epigenetic heterogeneity of diffuse gliomas, we present a comprehensive
analysis of DNA methylation of a large number of spatially
separated samples taken from regions with and without
imaging abnormalities. We devised a 3-dimensional reconstruction of the DNA methylation landscape for each
tumor, with particular consideration to the variable ratios of
tumor and nonmalignant cells in each sample. These ratios
are quantified as tumor purity using a methylation-based
metric that, although not being the perfect test due to nonzero levels of tumor purity in nonmalignant samples,17 has
proven to be a major confounder in genomic analyses.18
Our analysis underlines the infiltrative nature of gliomas beyond visible tumor boundaries and demonstrates a rather
homogeneous DNA methylation landscape across space.

Methods
Sample Acquisition and Study Design
A schematic overview of the study design is given in
Figure 1. The exploration cohort consisted of 16 patients
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• DNA methylation subtype is stable across glioma specimens from the same tumor

2056

Verburg et al. Spatial concordance of epigenetic glioma classification

A

DNA Isolation

B

DNA isolation was performed by adding proteinase K
and incubating at 56°C using the QIAamp DNA Mini Kit
(Qiagen). DNA was quantified using a Qubit Fluorometer
(Thermo Fisher). Genomic DNA was bisulfite converted
using the QIAamp DNA FFPE Tissue Kit (Qiagen).

Sampling in different imaging regions
No abnormalities
on imaging
FLAIR abnormalities
Contrast
enhancement

Data collection per sample:

C

Histology

D

Molecular

Qualitative

Methylation

Cell density
and MIB1-index

CNV

E

Imaging

Fig. 1 Graphical overview of the methods. A. Multiple preoperatively planned stereotactic biopsies were taken from each patient
tumor. B. Biopsies were acquired in regions in and outside imaging
abnormalities. C. Acquired tissue was subject to comprehensive
histological (C), molecular (D), and imaging (E) analysis.
  

with an untreated initial diffuse glioma, treated at the
Amsterdam UMC, location VU medical center (VUmc),
Amsterdam, the Netherlands. Patients’ characteristics
are given in Supplementary Table 1. All patients were
participants of the FRONTIER study of which the protocol
has been published.19 This protocol was approved by the
Medical Ethics Committee of the VUmc and registered in
the Dutch National Trial Register (www.trialregister.nl,
unique identifier NTR5354). Sampling was performed,
using a stereotactic biopsy procedure preceding the craniotomy, to obtain 2 samples of each biopsy location for,
respectively, Formalin-Fixed Paraffin-Embedded (FFPE)

DNA Methylation Profiling by Microarray
Data were processed using the minfi packages in R (R
Foundation for Statistical Computing, Vienna, Austria).
Data from the 450k (IlluminaHumanMethylation450k.
ilmn12.hg19) and EPIC platforms (IlluminaHumanMethyl
ationEPICanno.ilm10b2.hg19) were processed separately.
Detection P values were calculated for each probe and
sample, and samples with an average detection P value
>.01 were removed from follow-up analysis. Data were
normalized using BMIQ from the wateRmelon package in
R. Probes on sex chromosomes and known cross-reactive
probes were removed, as were probes mapping to known
SNPs and probes with a detection P value >.01. Finally,
data from different platforms were merged.

DNA Methylation-Based Classification
Glioma methylation subtype classification was performed
using L2-regularized logistic regression using the R
package LiblineaR. Classifiers were trained and evaluated
on a set of common probes from TCGA glioma samples
with known methylation subtypes. The classes LGm6-GBM
and PA-like were merged into a single class LGm6-PA as
the separation between these classes was based on phenotype. To improve the classification accuracy of samples with
low tumor purity, DKFZ controls were added to the classifier as separate classes. DKFZ DNA methylation classification was performed using the molecular neuropathology
classification tool (version 11b4).16 Briefly, the software
preprocesses, normalizes, and performs batch adjustment
on raw DNA methylation data to generate probabilistic estimates for each defined tumor subtype. The tumor subtype
with the highest probability was selected as the classification. Samples with a subclassification accuracy lower than
0.5 were assigned to the main DKFZ class in accordance
with the Molecular Neuropathology guideline.
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and Molfix© (patients 1-8) or snap-frozen (patients 9-16)
fixation. Samples were obtained from regions with and
without abnormalities on T1c and FLAIR MRI in accordance with the study protocol. All procedures were carried out in accordance with the Declaration of Helsinki.20
Written informed consent was obtained from all patients.
The validation cohort comprised 11 patients with 61
FFPE samples from multi-sector sampling of an untreated
diffuse glioma treated at the Toronto Western Hospital,
Toronto, Canada or UCSF Brain Tumor Center, San
Francisco, CA, USA. In addition, 64 FFPE samples from
64 patients without a glioma from the German Cancer
Network served as controls.

  
Stereotactic multi-region
image guided biopsies
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DNA Copy Number Aberrations Inferred From
EPIC Microarray
Using the R/Conumee package, copy number aberrations
were inferred from the 450k and EPIC array data. Merged
data from the control samples were used as a baseline
control for all analyses. Genomic data were used to calculate aneuploidy.

Immunohistochemistry and Qualitative
Assessment
FFPE samples from the exploration cohort were stained
using hematoxylin and eosin (HE) and MIB-1. Two expert
neuropathologists independently, blinded for imaging results, assessed the presence or absence of tumor in each
sample. Consensus was obtained in case of disagreement.
The patient’s histopathological diagnosis was made based
on resection material using routine procedures and according to the WHO 2016 criteria.22

Histopathological Analysis of Whole-Slide Scans
Using a Hamamatsu Nanozoomer XR, FFPE slides stained
with HE and MIB-1 of each sample were digitalized. The ×40
magnification images were converted to multiple mosaic
images using NDPITools software. Cellularity, defined as
the number of cells per square millimeter, was calculated
with Cellprofiler. Proliferation index, defined as percentage
of Ki-67-positive nuclei of all nuclei, was calculated using
locally developed software.

Radiologic Evaluation of Sample Locations
Standard imaging sequences from the patients in the exploration cohort included T1-, T2-, T2/FLAIR, and T1c MRI.
For each sample location, the presence of an abnormal
signal for each imaging sequence was independently assessed by a neurosurgeon and neurosurgical resident
with ample experience in glioma imaging. Consensus was
obtained in case of disagreement.

Sample-to-Tumor Surface Distance
Tumors were segmented on FLAIR and, in case of contrast
enhancement, also on T1c MRI, using Brainlab Software, by

Statistical Analysis
Median values with interquartile range were used to describe non-normally distribute data. Mann-Whitney U
test was used to compare distributions between subgroups. Correlations were calculated with the Spearman or
Pearson correlation and compared using Fisher z transformation. Comparison of percentages between subgroups
was performed using Fisher test normalization and scaling
of purity measurement modalities was performed by subtracting the mean and dividing by the standard deviation.
To compare absolute purity estimates, the normalized
and scaled purity measurements were rescaled using the
PAMES mean and SD. P values <.05 were considered statistically significant. R (version 3.5.3) was used for all statistical analyses.

Heterogeneity Analysis
Each probe per patient was classified as methylated (B >
0.3) or unmethylated (B < 0.3). A table of all possible pairwise combinations of samples was generated. Each pair of
samples was evaluated for heterogeneity by counting the
number of identical (homogeneous) probes, the number
of differing (heterogeneous) probes, and percentages
were subsequently calculated. Each pair was annotated according to the metadata for each sample in the comparison.
For each patient and sample type, we tabulated all possible combinations of any number of samples, iteratively
including between 1 and the total number of possible samples. The proportion of heterogeneous and homogeneous
probes was calculated when considering each sample
in a given set. For each patient/sample type and sample
number, we then calculated the mean and standard deviation of the proportion heterogeneous across all sets.

Results
We obtained 133 multi-region image-guided samples from
8 patients (6 glioblastoma, IDH-wildtype, 2 glioblastoma,
IDH-mutant) with an enhancing tumor (76 samples) and
8 patients (6 diffuse astrocytoma, IDH-mutant, 1 glioblastoma, IDH-wildtype and 1 oligodendroglioma, IDH-mutant
and 1p19q codeleted) with a non-enhancing tumor (47
samples) (Figures 1 and 2). In enhancing gliomas, 12 samples were taken outside both T1c and FLAIR abnormalities
(T1c−/FLAIR−), 44 samples outside (T1c−/FLAIR+), and 20
inside T1c abnormalities (T1c+/FLAIR+). In non-enhancing
gliomas, 16 samples were taken outside (FLAIR−) and
41 inside FLAIR abnormalities (FLAIR+). The maximum
sample-to-tumor surface distance in enhancing tumors
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DNA methylation measurements of tumor purity included
the PAMES (Purity Assessment from clonal MEthylation
Sites) algorithm and simplicity score.17,21 For the PAMES
nonmalignant central nervous system, samples from the
German Cancer Research Center (DKFZ) were used as a
control. PAMES operates in 3 steps. First, area under the
curves are calculated for each probe discriminating between tumor and normal. Second, a selection of the most
informative probes is made. Third, tumor purity is calculated on input samples using these probes.

a neurosurgical resident with ample experience in glioma
imaging. The segmentations and sample coordinates were
exported in 3D T1c MRI space. Sample-to-tumor surface
distances were obtained, using Matlab, by calculating the
distance between the sample coordinate and the nearest
surface coordinate of the tumor segmentation, using
FLAIR for non-enhancing and both FLAIR and T1c MRI for
enhancing tumors.

NeuroOncology

Methylation Purity Estimation and
Simplicity Score
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Tumor Purity Accounts for a Considerable
Amount of Variation in DNA Methylation Profiles
Since nonmalignant cells in a sample influence molecular tumor assessment,21 we sought to quantify tumor
purity, defined as the ratio of tumor to nonmalignant
cells. We evaluated and compared several methods of
tumor purity estimation based on histology, MRI, DNA
methylation, and DNA copy number (Supplementary
Figure 1A and B). DNA methylation-based purity estimates, PAMES provided the strongest correlations with
all other features.17 There was no difference in tumor purity between samples from IDH-mutant and IDH-wildtype
tumors (Supplementary Figure 1C). WHO subtype was
associated with tumor purity (Kruskal-Wallis P < .001),
with the highest tumor purities in oligodendroglioma,

IDH status
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Percent tumor
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Fig. 2 Overview of 133 samples in 16 patients with initial diffuse glioma. Samples are numbered in order of tumor purity for each patient. First
row = IDH status with + representing a mutation, 1p/19q status with + representing a codeletion, and contrast enhancement with + representing
the presence of contrast on T1c MRI. Second row = tumor purity assessed with PAMES. Third row = 3D reconstruction of FLAIR (yellow), T1c
MRI (red) abnormalities, and sample locations. Due to the 2D representation of 3D object samples behind and outside the abnormalities might
appear to be within the abnormalities. Fourth row = Euclidean distance (mm) between sample coordinate and tumor surface assessed with FLAIR
(yellow) and T1c MRI (red). Negative values indicate samples obtained within the tumor volume. Fifth row = the presence of abnormalities on
FLAIR (top) and T1c MRI (bottom) at the sample location. Sixth row = median cellularity and percentage of MIB1-positive cells of the sample, and
final row = consensus assessment of tumor presence by 2 neuropathologists. Abbreviations: FLAIR, fluid-attenuated inversion recovery; IDH,
isocitrate dehydrogenase; MRI, magnetic resonance imaging; PAMES, Purity Assessment from clonal MEthylation Sites; T1c, contrast-enhanced
T1-weighted.
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IDH-mutant and 1p/19q codeleted and the lowest for glioblastoma, IDH-mutant (Supplementary Figure 1D), most
likely due to the known admixture of nonmalignant cells
in grade IV diffuse glioma.23 This association between
grade and tumor purity is in line with a recent comprehensive analysis of TCGA samples.18
We performed a principal component analysis of the
DNA methylation data to elucidate drivers of differences in methylation (194 samples, Figure 3A). Included
in the analysis were samples from a second cohort consisting of 61 multi-sector tumor samples from 11 gliomas
(5 diffuse astrocytoma, IDH-mutant, 4 glioblastoma, IDHwildtype, 1 anaplastic astrocytoma, IDH-mutant, and 1
anaplastic oligodendroglioma, IDH-mutant and 1p19q
codeleted).16,24,25 The first principal component (percentage
of variance 71.2%) separated samples based on IDH status
(Figure 3A). The second principal component (percentage
of variance 5.8%) was associated with tumor purity, as
evidenced by the linear increase in tumor purity and the
samples from the control cohort (Figure 3B). These findings indicate that tumor purity accounts for a considerable
amount of variation in DNA methylation profiles.

was 36.5 mm and 25.6 mm, respectively, assessed with T1c
and FLAIR MRI. In non-enhancing tumors, the maximum
sample-to-tumor surface distance was 22.5 mm assessed
with FLAIR MRI.

Cellularity
Percent MIB1
positive cells (×103 cells/mm2)
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Fig. 3 Exploration of spatial distribution of DNA methylation-based subtypes. A. Principal component analysis of exploration and validation cohort (samples = 194). B. Correlation between the second principal component and tumor purity, with the correlation calculated with Pearson R.
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DNA Methylation Heterogeneity Is a Function
of Space

DNA Methylation-Based Classification Is Highly
Conserved in Space After Adjusting for Tumor
Purity and Classification Ambiguity
To establish the relationship between DNA methylationbased classification and tumor purity, we inferred sample
subtypes based on 2 previous published classifiers
(Supplementary Figure 2A),15,16 which showed a large
conformity for classification families (4.6% discordance,
Supplementary Figure 2B) and slightly lower conformity
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To precisely quantify DNA methylation heterogeneity, we
performed pairwise comparisons of binarized methylation values between samples. The vast majority of probes
were homogeneously methylated (mean 0.93, range
0.83-1.0) between samples, suggesting that only a small
fraction of probes is responsible for all intratumor heterogeneity. Similar trends have been observed in comparisons of nonmalignant samples from the same lineage.26
Unsurprisingly, any 2 samples from different unrelated
tumors showed less probes with identical methylation
(mean 0.93 ± 0.02) compared to any 2 samples from the
same tumor (mean 0.96 ± 0.03). However, this difference
was subgroup-dependent. For example, any 2 samples
from 2 unrelated IDH-mutant tumors show more similarity on average than any 2 samples from 2 unrelated
IDH-wildtype tumors (Figure 4A), likely related to the
propensity of (G-CIMP-positive) IDH-mutant tumors to
uniformly methylate. As expected, a higher degree of heterogeneity can be observed when comparing samples
classified as nonmalignant to samples classified as tumor,
based on DNA methylation classification, within the same
patient. Any 2 IDH-wildtype tumor samples from the same
patient show a comparable degree of heterogeneity when
compared to 2 nonmalignant samples from the same patient (Kolmogorov-Smirnov P = 1.0, pink and green dashed
lines). In comparison, any 2 IDH-mutant tumor samples
from the same patient demonstrate less heterogeneity
compared to any 2 nonmalignant samples from the same
patient (Kolmogorov-Smirnov P < .001). These findings
may reflect the clonal nature and shared ancestry of IDHmutant tumor cells, whereas specimens are classified as
nonmalignant harbor cells from a mixture of lineages.
To assess the impact of additional samples on tumor
heterogeneity, we calculated the percentage of identical
probes pooling any number of samples per patient, separating samples classified as tumor and nonmalignant
(Figure 4B). The majority of heterogeneity was captured
by the first 2 samples per patient. Although additional
samples further contributed to overall heterogeneity,
the change in heterogeneity decreased with each additional sample. Next, we investigated the relation between
sample-to-sample distance and heterogeneity. These were
positively correlated for both nonmalignant and tumor
samples (Figure 4C). These results suggest that heterogeneity is a function of space and that increased physical separation between cells increases cell-to-cell heterogeneity.

for family subtypes (12.4% discordance, Supplementary
Figure 2C). As expected, samples with a low tumor purity were assigned a control subtype whereas high tumor
purity samples were assigned a tumor subtype when assessed by the TCGA classifier (Supplementary Figure 2D).
The differences in subtype assignment and its relation to
tumor purity were clearly captured by the principal component analysis (Figure 3A). There were no significant differences between the tumor purity of the different tumor
subtypes in the exploration dataset (Supplementary Figure
2E) while in the validation dataset (Supplementary Figure
2F), the tumor purity was lower in the Classical-like compared to Mesenchymal-like subtype, which are methylation
subtypes based on unsupervised hierarchical clustering
with a majority of, respectively, Classical and Mesenchymal
expression subtypes as described by Verhaak et al.27 To explore the heterogeneity of tumor subtypes within a tumor,
we analyzed which tumor subtypes were recognized
within each patient across the core and validation dataset.
The majority of patients (24 of 27) did not show heterogeneity in tumor subtype as assessed by the TCGA classifier (Figure 5). In 3 patients (Toronto-02, VUmc-05, and
VUmc-17) with TCGA tumor subtype heterogeneity, the 1
(VUmc-05, VUmc-17) or 2 (Toronto-02) discordant samples
were the lowest purity tumor sample identifying tumor purity as the confounding factor for the found heterogeneity
(Supplementary Figure 3A). Also, the prediction accuracy
of tumor samples was lower in patients with subtype heterogeneity (mean prediction accuracy 71.0%) than without
(mean 94.9%, P < .001).
When we classified samples according to the DKFZ classifier, no heterogeneity was found for the main classes
(Supplementary Figure 3B and C). Heterogeneity of main
class subtypes, so-called family members, was found in 8
patients (VUmc-02, VUmc-04, VUmc-07, VUmc-14, VUmc-17,
Toronto-03, UCSF-01, and UCSF-18). Both tumor purity and
prediction accuracy were lower in tumor samples of these
8 patients with subtype heterogeneity (mean tumor purity
75.9 ± 0.09 and mean prediction accuracy 73.4 ± 14.9) compared to tumor samples of patients without heterogeneity
(mean 78.1 ± 10.9, P = .046 and 87.8 ± 18.0, P < .001, respectively), suggesting tumor purity and prediction accuracy
as potential confounding factors for the observed heterogeneity in these patients (Supplementary Figure 3D). In 2
patients (VUmc-02 and VUmc-17), the discordant samples
were the lowest tumor purity, although the absolute difference in tumor purity was small. In 3 patients (Toronto-03,
UCSF-01, and UCSF-18), the discordant samples were the
lowest prediction accuracy, although the absolute difference in prediction accuracy was small except for patient
UCSF-01. Three patients (VUmc-04, VUmc-07, and VUmc-14)
showed variable tumor purity and prediction accuracy of
the tumor samples suggesting true heterogeneity. To validate the possible heterogeneity in these patients, we evaluated the histological and imaging data that was available
for the exploration cohort. The only difference we found between subtypes was higher cellularity (P = .016) and more
frequent contrast enhancement on T1c (P < .001) in A IDH,
HG samples compared to A IDH samples (Figure 6A). This
confirmed the true heterogeneity in patient VUmc-04, with
both A IDH, HG samples having the highest cellularity and
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showing contrast enhancement on T1c (Figure 6B). In the 4
glioblastoma patients with multiple subtypes, neither histology nor imaging could confirm or reject the subtype heterogeneity (Figure 6C). Therefore, we conclude there is true
DNA methylation subtype heterogeneity in patient VUmc04, based on DNA methylation, histology, and imaging
data, and patients VUmc-07 and VUmc-14, based on DNA
methylation data. Based on all available data, it remains
unclear if there is true heterogeneity in the remaining
5 patients. Although not statistically significant, all true
heterogeneous patients had a glioblastoma (chi-squared
P = .17), yet heterogeneity was not related to IDH status
(chi-squared P = .73). Overall in our cohort, a low frequency
of true spatial heterogeneity of DNA methylation-based
subtypes was observed (14%, 3 of the 22 patients), when
taking tumor purity and prediction accuracy into account,
yet possible heterogeneity cannot be ruled out in another
5 (19%) patients.
Since O6-methylguanine-DNA methyl-transferase (MGMT)
promoter methylation status is an important prognostic
and predictive marker we assessed its spatial distribution.
Heterogeneity was found in 30% of patients and was not related to tumor purity (Pearson correlation P = .19), IDH status,
histology or DNA methylation classification heterogeneity
(chi-squared P = 1.0, P = .76, and P = .78, respectively).

DNA Methylation Abnormalities Extend Beyond
Standard MRI Boundaries
To understand the spatial distribution of glioma infiltration, we analyzed the correlation of tumor purity and subtypes with the distance to the tumor surface assessed with
T1c for enhancing and FLAIR MRI for non-enhancing tumors. As expected, the distance of samples to the tumor
surface showed a linear relationship with tumor purity
(Supplementary Figure 4A). In non-enhancing tumor, samples classified as Cortex were found further away from
the radiological tumor boundaries than all the other subtypes (Supplementary Figure 4B). Yet, in enhancing tumor,
this difference was not found, possibly indicating a more
diffuse infiltration pattern of enhancing tumors. When
evaluating the infiltration pattern in the histological subgroups, no difference was found except that distance to
tumor surface in 1 oligodendroglioma (median −7.9 mm,
IQR −14.5 to −3.9 mm) was lower than in IDH-mutant diffuse astrocytoma (−3.2 mm, −6.3 to 3.6 mm, P = .047)
(Supplementary Figure 4C).
As anticipated, in enhancing tumors the T1c+/FLAIR+
region showed the highest tumor purity, followed by the
T1c−/FLAIR+ and T1c−/FLAIR− (Supplementary Figure 5A).
In non-enhancing tumors, tumor purity was higher in the
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FLAIR+ than the FLAIR− region. Interestingly, samples
taken from regions outside standard imaging abnormalities (FLAIR− in non-enhancing and T1c−/FLAIR− and T1c−/
FLAIR+ in enhancing tumors) showed a tumor subtype in
36% and 17% of enhancing and non-enhancing gliomas,
respectively (Supplementary Figure 5B). Conversely, samples taken from within the standard imaging abnormalities
showed a nonmalignant subtype in 35% of enhancing tumors, which is most likely due to necrosis in these samples.
In non-enhancing tumors, 15% of samples within the FLAIR+
region showed a nonmalignant subtype. Tumor presence,
assessed as the ratio of tumor and nonmalignant TCGA subtypes, in the different imaging regions was comparable between histological subgroups (all chi-squared tests P > .05)
(Supplementary Figure 5C). Samples with tumor subtypes
were found up to 24 mm outside imaging abnormalities.
These findings support the diffusely infiltrative nature of
these tumors and corroborate the notion that standard MRI
does not capture the true extent of diffuse glioma infiltration.

Discussion
This study represents a comprehensive analysis of spatially separated samples in diffuse glioma.The combination

of histological, radiological, and DNA methylation data enabled us to explore the spatial contexts of tumor purity,
epigenetic molecular subtypes, and tumor heterogeneity.
Our study demonstrates that in most tumors, molecular
subtypes are stable and homogeneous after considering
tumor purity. Moreover, gliomas are diffusely infiltrative
tumors, and our data clearly show that they indeed extend beyond the tumor boundaries found on MRI. Finally,
in our study, the extent of heterogeneity in tumor samples
was predominantly equal to or less than in nonmalignant
samples.
Information on the spatial heterogeneity of epigenetic
molecular subtypes in the literature is limited. A recent
study reported intratumor DNA methylation-based subtype heterogeneity in 5 of the 12 glioblastomas in their
cohort.28 We were unable to confirm this extent of heterogeneity in our study. The differences may be explained
by our approach to account for tumor purity prior to determining intratumoral epigenetic subtype classification.
The non-purity–related heterogeneity that was found
could be explained by focal malignant progression in
patients with an IDH-mutant astrocytoma, while cellular
state plasticity, as described by Neftel et al,8 might be an
explanation for the coexistence of both mesenchymal and
RTK II subtypes in one of the IDH-wildtype glioblastoma
patients. Although technically difficult,29 future single-cell
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DNA methylation profiling can be expected to drastically
increase our understanding of DNA methylation classification heterogeneity. MGMT promoter methylation status
proved to be more heterogeneous than DNA methylation
subtypes, which is most likely due to the use of 2 probes
for the MGMT status compared to ~1000 probes for the
DNA methylation subtype.
We observed that samples obtained outside standard
imaging abnormalities, on FLAIR in non-enhancing and
on T1c MRI in enhancing gliomas, displayed similar epigenetic molecular subtypes as the samples from the
tumor core. The fraction of tumor cells per specimen
varied between the different MRI regions, with lower
fractions in regions outside of imaging abnormalities.
The presence of tumor tissue outside standard imaging
abnormalities is well known.4,5 Our results suggest that
spatial imaging heterogeneity in glioma is associated
with tumor purity and not with epigenetic heterogeneity,
although heterogeneity at the genomic and mutational
level as cause cannot be excluded and has recently been
reported for progressive IDH-mutant astrocytoma.30 This
was confirmed by the strong correlation between tumor
purity and the imaging score. Our observations imply
that a viable part of the tumor, especially in IDH-wildtype
glioblastomas, is left behind after resection of standard
imaging abnormalities.
A limitation of this study is the difficulty of assessing the
true tumor purity since there is no gold standard. Still, we
have compared many tumor purity metrics and choose
the most representative of those. Another limitation is
the evaluation of tumor heterogeneity by bulk DNA methylation analysis instead of single-cell analysis, although
correlating imaging data with single-cell analysis might
prove difficult due to the different levels of detail. Finally,
the use of T1c and FLAIR MRI for the assessment of tumor
to sample distance is a limitation, since these modalities
are known to be less accurate for the detection of diffuse
glioma infiltration.31 However, they are still the current
standard imaging and therefore represent the daily practice of glioma treatment.
In conclusion, we demonstrate that DNA methylation
subtypes in diffuse glioma show little intratumoral heterogeneity and are uniform across the different imaging
regions, underscoring the diffuse infiltrative nature of
this disease and the robustness of DNA methylation
subtypes.
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